Skip to main content
. 2015 Aug 20;11(11):2705–2715. doi: 10.1080/21645515.2015.1019186

Figure 1.

Figure 1.

Ex vivo ELISpot IFN-γ activities of infectivity controls. Five infectivity controls from the DNA/Ad trial and 4 infectivity controls from the AdCA trial were used. The associations of fold-changes of pre-CHMI and post-CHMI activities with pre-CHMI activities are shown as log-transformed values, and the dotted line represents no-change. The shaded box shows ±1.5 range (log ±0.18)-. (A) CSP: the fold change was ≤1.5, except one outlier, and all 9 subjects remained negative after CHMI. (B) AMA1: the fold change of all subjects was <1.5, and 6/9 subjects remained negative after CHMI, but 3/9 subjects developed positive activities after CHMI each to a single AMA1 peptide pool (not shown).